alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
November 6, 2018

Via the CFTC Web Submission Portal

Assistant Secretary of the Commission for FOIA Matters

Commodity Futures Trading Commission

Three Lafayette Centre

1155 21st Street, N.W.

Washington, D.C. 20581

Re: FOIA Confidential Treatment Request: Petition Pursuant to Regulation 145.9(d)

To Whom It May Concern:

On this date, trueEX LLC (“trueEX”) submitted a revised notice, 2018-08S, to the 

Commodity Futures Trading Commission (the "Commission") via the Commission Portal 

to notify it of the fees trueEX intends to charge for transactions in trueDigital Products, 

and a Designated Market Maker Program for trueDigital Products. Revisions were made 

to Section C of Exhibits B-1 nd B-2. Exhibits A-2 and B-2 are the Confidential Materials

for which trueEX is requesting confidential treatment. 

By this petition, trueEX requests confidential treatment pursuant to Section 145.9(d) of 

the Commission’s regulations of the Confidential Material. A copy of this Confidential 

Material is attached. 

Pursuant to Sections 8(a) of the Act, and Commission Regulation § 145.9(d), trueEX 

requests confidential treatment of the Confidential Material on the grounds that disclosure 

of such material would reveal trade secrets of trueEX and/or reveal confidential 

commercial information of trueEX. The Confidential Material is proprietary to trueEX and 

contain highly sensitive and confidential business and technology information; in addition 

to violating trueEX’s proprietary rights, the disclosure of the Confidential Materials would 

grant competitors an unfair competitive advantage and/or compromise the competitive 

advantages possessed by trueEX. Accordingly, trueEX is requesting the Commission to 

take appropriate steps to keep Confidential Material submitted to them confidential and 

to restrict the re-distribution of the Confidential Material.

Pursuant to Commission Regulation § 145.9(d)(5), trueEX hereby requests that the 

Confidential Material be afforded confidential treatment in perpetuity.

trueEX requests that the Commission notify the undersigned immediately after receiving 

any FOIA request, any court order, subpoena, or summons seeking to access the 

Confidential Material in whole or in part. trueEX further requests notification (through the 

undersigned) in the event that the Commission intends to disclose the Confidential 
Material in whole or in part to Congress or to any other governmental agency or unit 

pursuant to Section 8 of the CEA. trueEX does not waive its notification rights under 

Section 8(f) of the CEA with respect to any subpoena or summons with respect to the 

Confidential Material in whole or in part. 

Should you have any questions regarding the above, please do not hesitate to contact 

me by telephone at (312) 320-8934 or by email at fran@trueex.com. 

Sincerely,

Fran Kenck 

Chief Compliance Officer

Attachment:

CFTC 2018-08S Exchange Fees and DMM Submission_revised.docx
# C_2021182EN.01005101.xml

| 10.5.2021 | EN | Official Journal of the European Union | C 182/51 |
| --- | --- | --- | --- |

10.5.2021

EN

Official Journal of the European Union

C 182/51

---

Judgment of the General Court of 17 March 2021 — FMC v Commission

(Case T-719/17) (1)

(Plant-protection products - Active substance flupyrsulfuron-methyl - Non-renewal of inclusion in the Annex to Implementing Regulation (EU) No 540/2011 - Assessment procedure - Proposed classification of an active substance - Precautionary principle - Rights of defence - Legal certainty - Manifest error of assessment - Proportionality - Principle of non-discrimination - Principle of sound administration - Legitimate expectations)

(2021/C 182/68)

Language of the case: English

Parties

Applicant: FMC Corporation (Philadelphia, Pennsylvania, United States) (represented by: D. Waelbroeck, I. Antypas and A. Accarain, lawyers)

Defendant: European Commission (represented by: X. Lewis, G. Koleva and I. Naglis, acting as Agents)

Re:

Application under Article 263 TFEU for the annulment of Commission Implementing Regulation (EU) 2017/1496 of 23 August 2017 concerning the non-renewal of approval of the active substance DPX KE 459 (flupyrsulfuron methyl), in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending Commission Implementing Regulation (EU) No 540/2011 (OJ 2017 L 218, p. 7).

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders FMC Corporation to bear its own costs and to pay the costs incurred by the European Commission, including those relating to the substitution procedure and the proceedings for interim measures. |
| --- | --- |

2.

Orders FMC Corporation to bear its own costs and to pay the costs incurred by the European Commission, including those relating to the substitution procedure and the proceedings for interim measures.

---

(1)  OJ C 22, 22.1.2018.

---
<PAGE>

                                                                    Exhibit 24.5

                                POWER OF ATTORNEY

I, S. Sanford Schlitt, a duly elected Director of COMDIAL CORPORATION, a
Delaware corporation, do hereby constitute and appoint Ralph R. Dyer and Carla
K. Luke, or either of them, my true and lawful attorneys-in-fact, each with full
power of substitution, for me and in my name, place and stead, in any and all
capacities (including without limitation, as Director of Comdial), to sign
Comdial's Annual Report on Form 10-K for the year ended December 31, 2002, which
is to be filed with the Securities and Exchange Commission, with all exhibits
thereto, and any and all documents in connection therewith, hereby granting unto
said attorney-in-fact and agent full power and authority to do and perform any
and all acts and things requisite and necessary to be done, and hereby ratifying
and confirming all that said attorney-in-fact and agent may do or cause to be
done by virtue hereof. This power of attorney shall not terminate upon my
disability.

Dated: 03/27/03


       /s/ S. Sanford Schlitt
       -------------------------------------
       S. Sanford Schlitt
# C_2018408EN.01005002.xml

| 12.11.2018 | EN | Official Journal of the European Union | C 408/50 |
| --- | --- | --- | --- |

12.11.2018

EN

Official Journal of the European Union

C 408/50

---

Judgment of the General Court of 25 September 2018 — Novartis v EUIPO — Chiesi Farmaceutici (AKANTO)

(Case T-182/17) (1)

((EU trade mark - Opposition proceedings - Application for EU word mark AKANTO - Earlier EU word mark KANTOS - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001))

(2018/C 408/64)

Language of the case: English

Parties

Applicant: Novartis AG (Basel, Switzerland) (represented by: L. Junquera Lara, lawyer)

Defendant: European Union Intellectual Property Office (represented initially by: P. Duarte Guimarães and J. Ivanauskas, and subsequently by J. Ivanauskas and D. Walicka, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Chiesi Farmaceutici SpA (Parma, Italy) (represented by: T. de Haan, P. Péters, and F. Folmer, lawyers)

Re:

Action brought against the decision of the First Board of Appeal of EUIPO of 9 January 2017 (Case R 531/2016-1) relating to opposition proceedings between Chiesi Farmaceutici and Novartis.

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Novartis AG to pay the costs. |
| --- | --- |

2.

Orders Novartis AG to pay the costs.

---

(1)  OJ C 161, 22.5.2017.

---
Case 1:07-cv-04462-AKH Document 40 Filed 11/09/2007 Page 1 of 2
Case 1:07-cv-04462-AKH Document 40 Filed 11/09/2007 Page 2 of 2
#### The People of the State of New York, Respondent, v Sylvester Bradley, Appellant.

Judgment, Supreme Court, New York County (Juanita Newton, J.), rendered on November 17, 1987, unanimously affirmed. The matter is remitted to the Supreme Court, New York County, for further proceedings pursuant to CPL 460.50 (5). No opinion. Concur—Kupferman, J. P., Carro, Rosenberger, Ellerin and Smith, JJ.
# fcmdata0206
600335672

Bloomberg SEF LLC

731 Lexington Avenue

New York, NY 10022

November 1, 2019

FOIA CONFIDENTIAL TREATMENT REQUEST

Submitted via FedEx, the Portal and via email

CFTC FOIA Compliance Office

Three Lafayette Centre

1155 21st Street, N.W.

Washington, D.C. 20581

Re: Freedom of Information Act (“FOIA”) Confidential Treatment Request for 

Information Submitted to the Commodity Futures Trading Commission 

(“Commission”) by Bloomberg SEF LLC, as operator of a swap execution facility

Ladies and Gentlemen:

Pursuant to Section 5c(c) of the Commodity Exchange Act (the “Act”) and Section 

40.6(a) of the regulations of the U.S. Commodity Futures Trading Commission (the

“CFTC”, or the “Commission”), Bloomberg SEF LLC (“BSEF”) as the operator of a 

swap execution facility, submitted to the Commission a rule amendment (the 

“Amendment”). 

Bloomberg SEF hereby requests that the Confidential Information (as defined below) be 

accorded confidential treatment on the grounds that it would reveal Bloomberg SEF’s

trade secrets and confidential commercial or financial information. We request this 

confidential treatment for an indefinite period. 

Please promptly inform the following of any request for the Confidential Information or 

its contents made pursuant to FOIA or the Commission’s rules so that we may 

substantiate the foregoing request for confidential treatment in accordance with Part 

145.9 of the Commission’s regulations.

David Levine

General Counsel

Bloomberg L.P.

731 Lexington Avenue

New York, NY 10022

The certification described above and attached as Annex A hereto is referred to herein as 

the “Confidential Information.”
U.S. Commodity Futures Trading Commission

Page 2

Pursuant to Part 145.9(d)(4) of the Commission’s regulations, we have marked each page 

of the Confidential Information with the words “Confidential Treatment Requested by 

Bloomberg SEF LLC” and have numbered each page of the Confidential Information 

with an identifying number and code, beginning with “BSEF-1119-0001” and ending 

with “BSEF-1119-0208.”

[signature page follows]
U.S. Commodity Futures Trading Commission

Page 3 

Please acknowledge receipt of this letter by stamping the enclosed copy of this letter and 

returning it via the pre-paid envelope included with the materials. 

Please contact the undersigned at (212) 617-3918 with any questions regarding this matter. 

Thank you for your attention to this matter. 

Very truly yours,

Devi Shanmugham 

Chief Compliance Officer

Bloomberg SEF LLC 

731 Lexington Avenue 

New York, NY 10022 

cc: Jonathan Lave, Division of Market Oversight, U.S. Commodity Futures Trading 

Commission (Email: JLave@cftc.gov) 
U.S. Commodity Futures Trading Commission

Page 4 

Annex A 

Confidential Information

Name of Confidential Information Identifying Number and Code

Rule Amendment Self-Certification BSEF-1119-0001–BSEF-1119-0208
#### CONVERSE *v.*MINNESOTA THRESHER MFG. CO. SAME v. FIRST NATIONAL BANK OF SUFFIELD.

ERROR TO THE SUPREME COURT OF ERRORS OF CONNECTICUT.

Nos. 75, 76.

Argued January 14, 1909.

Decided January 25, 1909.

A judgment of the highest court of Connecticut,- involving the liability of stockholders under, provisions in the constitution of Minnesota; reyersed on the' authority of *Bernheimer*v. *Converse,*206 U. S. 516.1

*568
      *Mr. Wm. Waldo Hyde*and *Mr. Charles Welles Gross*for plaintiff in error.

No appearance, for defendants in error.

[ The leading headnote in *Bernheimer*v. Converse, 206 U. S. 516, referred to; is as follows;

“The court in this case followed the judgment of the highest court of , the State in determining that a corporation was not within the exception, *568constitutional and statutory, as to stockholders’ liability in favor of certain classes of corporations. Where, as in Minnesota, stockholders’liability is fixed and measured by the constitution, a stockholder upon acquiring his stock incurs an obligation arising from the constitutional provisions, and as such capable of being enforced in the courts not only of that State but of another State and of the United States.”]

*Per Curiam:*

Judgments reversed with costs on the authority of *Bernheimer*v. *Converse,*206 U. S. 516, and cases remanded for further proceedings in conformity to law.
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

WILLIE E. POLITE,

Petitioner :

:

:

:

:

:

:

:

:

:

: No. 363 EAL 2017

Petition for Allowance of Appeal from

the Order of the Superior Court

ORDER

PER CURIAM

AND NOW , this 20th day of December, 2017

, the Petition for Allowance of

Appeal and Motion for Leave to Supplement are DENIED

.
LedgerX Fee Schedule

(as submitted March 4, 2020)

Withdrawal Fees

1. A USD withdrawal fee of .005 .001 BTC will be charged to the Participant per BTC 

withdrawal.
---

Exhibit 32.1

CERTIFICATION PURSUANT TO18 U.S.C. Section 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002

In connection with the Quarterly Report of AM Oil Resources
& Technology Inc. (now Medical Care Technologies Inc.)(the "Company")
on Form 10-Q/A for the period ended June 30, 2009 as filed with the Securities
and Exchange Commission on the date here of (the "report"), I, Ning C. Wu, Chief
Executive Officer and Chief Financial Officer of the Company, certify, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

| | (1) | The Report fully complies with the requirements of
      Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
  and                                    
| | --- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------
| |     |                                                                                                                                                                  
| | (2) | The information contained in this Report fairly presents,
      in all material respects, the financial condition and results of
      operations of the Company.

Dated this 9th day of April, 2010.

NING C. WU Ning C. Wu Chief
Executive Officer and Chief Financial Officer

---
First Goldwater Resources Inc


First Goldwater Resources Inc.







June 7, 2004

Memo to:  Gaston Reymenants

From     :   W. Murray




Re Engagement as Vice President Marketing




The private interests of the Boleo copper/cobalt project were merged into First Goldwater Resources Inc. (FGW); a public company trading on the Vancouver Stock Exchange (TSX-V).  The deal was finally approved by the TSX-V on April 18, 2004.  FGW will shortly have a name change, to more accurately reflect its business, and will be called Baja Mining Corp.




FGW needs senior representation to obtain off-take agreements for its planned metal production which is currently estimated to be 50,000 tpy of copper cathode; ~3,000 tpy of contained cobalt and 18,000 tpy of contained zinc.  The Boleo pre-feasibility study completed in 1997 only considered the production of copper metal, cobalt metal and zinc metal on site.  After recent contacts with industry, it is indicated that there are large markets for cobalt sulphate (and cobalt carbonate) and zinc sulphate.  It is FGW’s objective to obtain off-take buyers for the value added cobalt and zinc products which will also allow significant capital cots reductions.




Since it is difficult to determine a definite program for your work, we would like to retain you in a senior capacity with FGW, pay a reasonable retainer, pay your expenses and have you participate in the reward scheme that we have planned for other core members of the FGW team.  I would like to confirm, in broad terms, your retainer:-




1.

Retainer.  US$2,000 per month.

2.

Expenses.  All out of pocket expenses to be paid by FGW on submission of, supported, expense reports.

3.

Options.  250,000 options at a price of C$0.75

4.

Finders Fee.  It is acknowledged that you have contacts in the industry who may wish to invest in the Boleo Project; either to secure long term metal supply or for project financing.  This is to confirm that you are able to receive a fee in respect of project monies raised as a result of your efforts and/or contacts.  FGW is required to follow TSX guidelines; e.g>$2 million allows a fee of 5% to be paid.




I trust this reflects our discussions.  If you are in agreement, I will have our lawyer complete a full agreement.







William Murray

VP Operations & Development




Suite 1880- 1066 West Hastings Street, Vancouver, B.C., V6E 3X1

Tel  604 685 2323   Fax  604 688 0426
Case 7:07-cv-05815-KMK-MDF Document 29 Filed 08/03/2007 Page 1 of 1
# Fixes

# Sheet2

# Sheet3
**Exhibit
      99.2**








CERTIFICATE
      PURSUANT TO


18
      U.S.C.
      SECTION 1350


AS
      ADOPTED PURSUANT TO


SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002




In
      connection with the Quarterly Report (the “Report”) on the Form 10-QSB of
      Portage Resources, Inc. (the “Company”) for the six months ended November 30,
      2007, as filed with the Securities and Exchange Commission on the date hereof,
      I, Martine Caron, Chief Executive Officer, President and Director, certify,
      pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and
      belief:





1.
      The
      Quarterly Report fully complies with the requirements of Section 13 (a) or
      15
      (d) of the Securities and Exchange Act of 1934, as amended; and





2.
      The
      information contained in this Quarterly Report fairly presents, in all material
      respects, the financial condition and results of operation of the
      Company.




Date:
      January 14, 2008




MARTINE
      CARON




Martine
      Caron


Chief
      Executive Officer,


President
      and Director











-1-
# C_2019139EN.01004801.xml

| 15.4.2019 | EN | Official Journal of the European Union | C 139/48 |
| --- | --- | --- | --- |

15.4.2019

EN

Official Journal of the European Union

C 139/48

---

Judgment of the General Court of 5 March 2019 — Eurosupport — Fineurop support v EIGE

(Case T-450/17) (1)

(Public service contracts - Tender procedure - Provision of a service for the implementation of a study on female genital mutilation - Rejection of a tenderer’s bid - Obligation to state reasons - Coherence between comments and the numerical score - Non-contractual liability)

(2019/C 139/47)

Language of the case: English

Parties

Applicant: Eurosupport — Fineurop support Srl (Milan, Italy) (represented by: M. Velardo, lawyer)

Defendant: European Institute for Gender Equality (represented by: V. Ost and M. Vanderstraeten, lawyers)

Re:

Application (i) under Article 263 TFEU for annulment of the decision of the EIGE of 8 May 2017 rejecting the tender submitted by the applicant in procurement procedure EIGE/2017/OPER/04 and the decisions selecting as successful the tender submitted by Company Y and awarding that contract to it, (ii) under Article 268 TFEU for an award of damages in respect of those decisions and (iii) in the alternative, for compensation for irregularities in the award of that contract.

Operative part of the judgment

The Court:

| 1. | Declares that there is no longer any need to rule on the decisions of the European Institute for Gender Equality (EIGE) of 8 May 2017 adopting the tender submitted by Company Y in the context of the EIGE/2017/OPER/04 tender procedure and awarding it that contract; |
| --- | --- |

1.

Declares that there is no longer any need to rule on the decisions of the European Institute for Gender Equality (EIGE) of 8 May 2017 adopting the tender submitted by Company Y in the context of the EIGE/2017/OPER/04 tender procedure and awarding it that contract;

| 2. | Annuls the decision of the EIGE of 8 May 2017 rejecting the tender which Eurosupport — Fineurop support Srl had submitted in the context of that procedure; |
| --- | --- |

2.

Annuls the decision of the EIGE of 8 May 2017 rejecting the tender which Eurosupport — Fineurop support Srl had submitted in the context of that procedure;

| 3. | Dismisses the action as to the remainder; |
| --- | --- |

3.

Dismisses the action as to the remainder;

| 4. | Orders Eurosupport — Fineurop support to bear 25 % of its own costs and the EIGE to bear its own costs and to pay 75 % of the costs incurred by Eurosupport — Fineurop support. |
| --- | --- |

4.

Orders Eurosupport — Fineurop support to bear 25 % of its own costs and the EIGE to bear its own costs and to pay 75 % of the costs incurred by Eurosupport — Fineurop support.

---

(1)  OJ C 357, 23.10.2017.

---
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 1 of 13
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 2 of 13
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 3 of 13
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 4 of 13
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 5 of 13
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 6 of 13
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 7 of 13
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 8 of 13
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 9 of 13
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 10 of 13
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 11 of 13
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 12 of 13
Case 1:07-cv-05869-PAC Document 1 Filed 06/21/2007 Page 13 of 13
CERTIFICATION
      OF CHIEF EXECUTIVE OFFICER AND


CHIEF
      FINANCIAL OFFICER


PURSUANT
      TO


18
      U.S.C.
      SECTION 1350,


AS
      ADOPTED PURSUANT TO


SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002








In
      connection with the accompanying Quarterly Report on Form 10-QSB of Buzz Media,
      Ltd. for the quarter ended August 31, 2007, I certify, pursuant to 18 U.S.C.
      Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
      of
      2002, to my knowledge, that:





|(1) | the
              Quarterly Report on Form 10-QSB of Buzz Media, Ltd. for the quarter
              ended
              August 31, 2007 fully complies with the requirements of Section 13(a)
              or
              15(d) of the Securities Exchange Act of 1934; and
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




|(2) | the
              information contained in the Quarterly Report on Form 10-QSB for the
              quarter ended August 31, 2007, fairly presents in all material respects,
              the financial condition and results of operations of Buzz Media,
              Ltd..
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




By:
            /s/
                Tiffany WalshName:
            Tiffany
                WalshTitle:
            Principal
                Executive Officer,
              Principal
                Financial Officer and DirectorDate:
            October
                15, 2007